ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
SUBSCRIBE: eNewsletter
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
The empagliflozin CV benefit was "astounding" and a first for any diabetes drug, but what does it actually mean?
Sodium glucose cotransporter 2 inhibitors act independently of insulin level and so can be used at various stages of type 2 diabetes disease progression. Latest findings, here.
Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.
Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.